Twenty‐five years ago, aberrant expression of FGFR1 was observed in pancreatic cancer.82 Moreover, the 2‐immunoglobulin‐like form of FGFR1 was reported to involve in aberrant autocrine and paracrine pathways in pancreatic cancer.82 One study showed that inhibition of FGFR‐1 decreased cell growth in vitro and retarded tumour‐forming potential in vivo in pancreatic cancer. The gene discussed is FGFR1; the disease is neoplasm.